Image via citybiz — regional US deals
Last updated
BioMarin Pharmaceutical Inc.: Ma Activity
BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.
Source: citybiz — regional US deals
The leadership read
Consolidation shifts the leadership question from growth to integration. For BioMarin Pharmaceutical Inc. in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: Backdrop: a 100.1 (Neutral) Talent Market Index (down 1.1 on the month) with Americas activity easing (-1.8pts).
BioMarin Pharmaceutical Inc.: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 25 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 119 days.
MitchelLake in this thematic
Also at BioMarin Pharmaceutical Inc. →
More signals across Biotech & Pharma
Ma Activity · Americas
Amgen →Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
Ma Activity · Americas
Biogen →Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
Ma Activity · Americas
Teva Pharmaceuticals →Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
Ma Activity · Americas
Bristol Myers Squibb →Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal
Ma Activity · Americas
Gilead Sciences →Gilead Sciences acquires Tubulis GmbH for $3.15B to expand oncology portfolio
Ma Activity · Americas
Bora Pharmaceuticals →Bora Group announced acquisition of MacroGenics' GMP manufacturing operations and CDMO business for US$122.5 million plus up to US$5 million contingent consideration. Includes biologics manufacturing facility in Rockville, Maryland with substantial backlog.
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search — Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record